Potential treatment for allergic disease including severe steroid resistant asthma

submit enquiry
Mouse lung asthma inflammation (left), suppressed by HpARI treatment (right)
Mouse lung asthma inflammation (left), suppressed by HpARI treatment (right)

University: University of Edinburgh

Sector(s): Healthcare & Pharmaceuticals, Life Sciences

About Opportunity:

Severe steroid resistant asthma is an allergic disease that affects around 5% of asthmatics, but requires 50% of the total NHS spend to treat. There are no treatments and it is considered as a major unmet need.

IL-33 cytokine release has been shown to be a critical step in a range of allergic diseases, and high IL-33 levels in the lung have been associated with severe asthmatic pathology. IL-33 has been proposed as a potential target for steroid-resistant asthma. Candidates that directly block released IL-33 are in development, but none of these prevent the release of IL-33 from necrotic cells or selectively bind only the active form of IL-33, which is required for therapeutic effect.


Our technology, HpARI, centres around a peptide derived from the secretions of a helminth parasite, and which we have shown blocks the release of IL-33 from cells, and binds to active IL-33 only. This dual strategy is a potentially more efficacious and efficient approach to treatment than current candidates.

HpARI suppresses allergic immune responses, lung pathology, and improves lung function through interference in the IL-33 pathway in in vivo and in vitro models. We have characterised the domains and binding sites necessary for activity, and the design of drugable peptides is currently underway.

Key Benefits:

  • A previously unknown mechanism to modulate IL-33
  • More efficient approach than binding active and inactive form of IL-33; lower concentration required for effect
  • Dual strategy differs from other anti-IL33 candidates
  • Current tools are ineffective in detection and blockade of active IL-33


  • Therapy for severe, steroid-resistant asthma therapy and other IL-33 mediated allergic disease.

IP Status:

UK priority filing


Please enter your name.

Please enter the name of the company you work for.

Is your company an SME?

Please select the country you are in.

Please select what part of the UK you are in.

Please select from the following options.

Please enter your email address.

To help us process your enquiry faster please enter some details about the information you are interested in.

Words remaining:

Related Opportunities

  • Telomerase Promoter - Cancer Therapies

    The University of Glasgow has developed a (Ad-hTR-NTR) which has been extensively tested on Ovarian cancer cells.

    Expires: Created:
  • SNP-based assay for analysis of MRSA

    This assay is a rapid and reproducible approach for epidemiological analysis of methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates. The assay identifies different strains on EMRSA-15, which is a major cause of hospital acquired MRSA infections in the UK and in other parts of the wo...

    Expires: Created:
  • Catanostics - Non-Invasive Early Stage Cataract Diagnosis & Severity Quantification tool

    Catanostics (Cataract Diagnostics) offers an alternative to the slit lamp currently used for cataract diagnosis before referring a patient for cataract surgery. Our non-invasive fluorescence scan offers "better diagnosis" through non-subjective analysis of data on cataract symptoms & severity lea...

    Expires: Created:
  • Transforming Pharmaceutical Crystal Forms

    The innovation provides a gas-induced method for phase-transforming organic solids, such as pharmaceutical crystals. The inventive method subjects the polymorphs of pharmaceutical agents to various pressures of gases (such as CO2, N2O, and CH4) to induce phase transform with ease.

    Expires: Created:
  • Sperm Motility Enhancers for Assisted Reproductive Technology

    Sperm Motility Enhancers: A Novel Strategy for Assisted Reproductive Technology (ART) based on the direct relationship between human fertility and sperm motility,the University of Dundee has successfully identified FDA-approved compounds with robust and effective stimulation on patient sperm motilit...

    Expires: Created:

Alerts Signup

Sign up to our technology alerts and be the first to hear about any new technology opportunities from Scotland's universities

Register Now for University Technology.com Alerts

Search Filter

Share this page

Use the buttons below to share these technology opportunities on your favourite social networking site. You can also share them from inside the individual opportunity.